Use of pharmacokinetic modelling to individualize FFP dosing in factor V deficiency. (23rd November 2012)

• Record Type: Journal Article
• Authors: Shakhnovich, V.; Daniel, J.; Wicklund, B.; Kearns, G.; Neville, K.
• Is Part Of: Haemophilia. Volume 19:Number 2(2013:Mar.)
• Page Start: 251
• Page End: 255
• Publication Date: 2012-11-23
• Subjects: Hemophilia -- Periodicals; 616.1572005
• DOI: 10.1111/hae.12045
• Languages: English
• ISSNs: 1351-8216

Abstract

<abstract abstract-type="main" id="hae12045-abs-0001"> <title>Summary</title> <p>Therapy with fresh frozen plasma (FFP) confers serious risks, such as contraction of blood‐borne viruses, allergic reaction, volume overload and development of alloantibodies. The aim of this study was to apply principles of pharmacokinetic (PK) modelling to individual factor content of FFP to optimize individualized dosing, while minimizing potential risks of therapy. We used PK modelling to successfully target individual factor replacement in an 8‐month‐old patient receiving FFP for treatment of a severe congenital factor V (FV) deficiency. The model fit for the FV activity vs. time data was excellent (<italic>r</italic> = 0.98) and the model accurately predicted FV activity during the intraoperative and postoperative period. Accurate PK modelling of individual factor activity in FFP has the potential to provide better targeted therapy, enabling clinicians to more precisely dose patients requiring coagulation products, while avoiding wasteful and expensive product overtreatment, minimizing potentially life‐threatening complications due to undertreatment and limiting harmful product‐associated risks.</p> </abstract>